Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunovant Inc (NQ: IMVT )

27.96 -0.01 (-0.04%)
Streaming Delayed Price Updated: 3:17 PM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immunovant Inc

< Previous 1 2 3 4 5 Next >
After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay
Immunovant, which jumped Wednesday on news from rival Biohaven, reversed course Thursday. 
Via Investor's Business Daily
IMVT Stock Earnings: Immunovant Misses EPS for Q4 2024
IMVT stock results show that Immunovant missed analyst estimates for earnings per share the fourth quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Biohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage Study
Biohaven shares drop as interim data from the Phase 1 study of BHV-1300 fell short of investor expectations. 
Via Benzinga
Why Bank of Montreal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Recap: Immunovant Q3 Earnings
Via Benzinga
Heico Posts Upbeat Earnings, Joins Surmodics, Abercrombie & Fitch And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump
The company says it's still running additional testing of the drug, calling the results "positive." 
Via Investor's Business Daily
Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom. 
Via InvestorPlace
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
Investors saw Chugai's experimental drug as a potential rival to Argenx's approved medicine, Vyvgart. 
Via Investor's Business Daily
Argenx Dives On Autoimmune Therapy Failure
A treatment for a skin-blistering condition failed to beat a placebo. 
Via Investor's Business Daily
Analyst Ratings for Immunovant
Via Benzinga
Where Immunovant Stands With Analysts
Via Benzinga
Recap: Immunovant Q2 Earnings
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024
Find out which under-the-radar biotech stocks have major catalysts on the horizon, and unlock their explosive growth potential. 
Via InvestorPlace
7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024
Unveil these standout Russell 2000 stocks, meticulously picked to harness the potential of the evolving market landscape in the 2024 surge. 
Via InvestorPlace
3 Top-Rated Russell 2000 Stocks Wall Street Analysts Are Loving Now: January 2024
Analyst ratings tell investors which stocks institutional investors like, here are three top-rated Russell 2000 stocks to consider in 2024 
Via InvestorPlace
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond
These five biotech companies could have a lot of room to run. 
Via The Motley Fool
Stock Market Rally Is In Merry Mood Heading Into Christmas Weekend: Weekly Review
Despite a Wednesday tumble, the major indexes are right at 2023 highs. 
Via Investor's Business Daily
Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings. 
Via Benzinga
Immunovant Scores Much-Needed Win Following Argenx-Led Sell-off
Immunovant reversed its fortunes Thursday following an Argenx-tied selloff Wednesday. 
Via Investor's Business Daily
Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50%
Immunovant Inc (NASDAQ: IMVT), on Thursday, released the results from the initial cohort of patients in an ongoing 24-week Phase 2 trial of batoclimab in  
Via Benzinga
Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Micron Posts Upbeat Sales, Joins Calliditas Therapeutics And Other Big Stocks Moving Higher In Thursday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow Jones futures gaining more than 150 points on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
From Roivant Sciences
Via GlobeNewswire
Why Steelcase Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Steelcase Inc. (NYSE: SCS) shares moved higher during Wednesday's session following quarterly results. 
Via Benzinga
FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 30 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review
Software earnings were strong, while the Fed is shifting toward rate cuts. 
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
From Roivant Sciences
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.